MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Malignant neoplasm of pancreas, unspecified (C25.9)

HealthDay 11 July at 04.04 PM

GLP-1 RAs May Reduce Risk for Some Obesity-Linked Cancers Versus Insulin in T2D

For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers (OACs) compared with insulin, according to a study published online July 5 in JAMA Network Open.Lindsey Wang, from Case Western Reserve University School of Medicine

Evalytics 15 April at 05.45 PM

There’s still no standard test to detect pancreatic cancer early. Scientists are working to change that

Researchers are striving for an early detection method for pancreatic cancer, aiming to improve survival rates. Liquid biopsy tests, like one achieving 97% accuracy in detecting stage I and II cancers, offer promise. Early detection is crucial as surgery becomes more viable, but challenges remain in developing widely applicable screening methods.

HealthDay 13 January at 12.12 AM

Substance Use Disorders on the Rise for Survivors of Specific Cancers

The prevalence of substance use disorder (SUD) seems to be elevated among survivors of certain types of cancer, according to a study published online Jan. 11 in JAMA Oncology.Katie F. Jones, Ph.D., from VA Boston Healthcare System, and colleagues describe cancer type-specific prevalence of SUD among adult cancer survivors in a cross-sec

HealthDay 12 January at 04.48 PM

Cancer Vaccine Safe, Induces T-Cell Responses for KRAS-Mutated Tumors

For patients with immunotherapy recalcitrant KRAS-mutated tumors, the cancer vaccine ELI-002 2P is safe and induces T-cell responses, according to a study published online Jan. 9 in Nature Medicine.Noting that the cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using Amphiphile (Amph)-modification of G12D and

HealthDay 21 December at 11.08 PM

MSI-H Colorectal Cancer Rarely Recurs After Immunotherapy Cessation

Most patients with microsatellite instability-high (MSI-H) colorectal cancer do not have recurrence after cessation of immunotherapy treatment, according to a study published in the December issue of Cancer Research Communications.Kristen Simmons, M.D., from the Baylor College of Medicine in Houston, and colleagues reviewed records fr

HealthDay 19 December at 04.59 AM

Outdoor Pollution Exposure Tied to Nonlung Cancers

Outdoor air pollution is tied to a higher risk for nonlung cancers in older adults, according to a study published online Aug. 1 in Environmental Epidemiology.Yaguang Wei, Ph.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues examined associations of 10-year exposures to fine particulate matter (PM2.

HealthDay 28 November at 05.03 PM

Recent Decline in Risk for CRC Recurrence Seen in Stage I to III Disease

From 2004 to 2019, the risk for recurrence of colorectal cancer (CRC) decreased in patients with stages I to III disease, according to a study published online Nov. 16 in JAMA Oncology to coincide with the annual meeting of the Danish Surgical Society, held from Nov. 16 to 17 in Copenhagen.Jesper Nors, M.D., from Aarhus University Hosp

Evalytics 20 November at 08.49 PM

New tumor marker can detect gastric cancer with nearly 90% accuracy

Researchers at Nagoya University have discovered that the protein SDF-4 is a highly effective marker for early detection of gastric cancer, with 89% sensitivity and 99% specificity. This breakthrough, published in Scientific Reports, indicates that simple blood tests for SDF-4 could significantly improve early diagnosis and treatment of various cancers, including gastric, esophageal, and colorecta

HealthDay 03 November at 03.28 PM

AI Getting Better at Detecting Skin Cancer

Artificial intelligence (AI) is increasingly accurate in detecting skin cancer, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Oct. 11 to 14 in Berlin.Kashini Andrew, M.B.B.S., from the University Hospitals Birmingham NHS Foundation Trust in the United Kingdom, and colleagues